Adalimumab-induced multiple sclerosis in a patient with IBD-related arthritis

Abstract

TNF blockers have revolutionized the management of immune-mediated inflammatory diseases. Despite their relatively safe profile, an increasing number of reported neurological adverse events suggest a role for TNF inhibitors in the induction of central and peripheral nervous system demyelination.